FierceBiotech

Medtronic expands reach of its latest TAVR valve with European approval

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest version of its transcatheter aortic valve replacement implant. Compared to ...
Tyler Morning Telegraph

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
Becker's ASC

Medtronic study: CoreValve TAVR system improves quality of life — 7 insights

Patients implanted with the CoreValve transcatheter aortic valve replacement showed strong blood flow and improved quality of life at five years post-implant, according to results from two Medtronic ...
AOL

Medtronic study puts spotlight on how one of its heart devices can help women

More and more medical studies show that heart issues in women are not only underdiagnosed but should be treated differently. A study Medtronic designed to test its Evolut TAVR (transcatheter aortic ...
FiercePharma

Medtronic backs push to activate heart valve disease patients as TAVR marketing heats up

Medtronic is pumping up its activation of heart valve disease patients. The company has partnered with an advocacy group for heart valve disease, Heart-Valve-Surgery.com, to create a digital platform ...
Medscape

SURTAVI: TAVR, Surgical Aortic-Valve Replacement Stand Toe-to-Toe in Intermediate-Risk Patients

WASHINGTON, DC — (Updated with commentary) The SURTAVI trial hit its noninferiority end point, making it the second prospective randomized trial to show transcatheter aortic-valve replacement (TAVR) ...
GlobalData on MSN

Medtronic announces two-year trial outcomes of Evolut TAVR

Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...
Hosted on MSN

Medtronic reports late-breaking data from TAVR system trial for aortic stenosis

Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...
FierceBiotech

Edwards rebuffs Medtronic annulus study with 5-year TAVR safety data focused on women

Two major players are vying for women’s hearts, but it’s not as romantic as it sounds. After Medtronic put forward a head-to-head study in April showing its transcatheter aortic valve replacement ...
MD&M East

Medtronic Breaks Out Strong TAVR Data at ACC

Medtronic reported late-breaking data on five-year outcomes from the Evolut Low Risk Trial. The Dublin-based company said data shows, vs. surgery, the Evolut transcatheter aortic valve replacement ...
The Motley Fool

Why Medtronic Stock Marched Higher on Monday

On Sunday, Medtronic published five-year data from a low-risk clinical trial of its Evolut transcatheter aortic valve replacement (TAVR) system. In the trial, TAVR, which assists patients suffering ...